Therapy with amphotericin B and other new antifungal agents.
D000475:Alkenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005437:Flucytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D051379:Mice; D009181:Mycoses / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013266:Stilbamidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013302:Streptomyces
D000475:Alkenes; D000935:Antifungal Agents; D010455:Peptides; D013266:Stilbamidines; D000666:Amphotericin B; D005437:Flucytosine